Podcasts about molecularly

  • 44PODCASTS
  • 89EPISODES
  • 44mAVG DURATION
  • ?INFREQUENT EPISODES
  • Mar 12, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about molecularly

Latest podcast episodes about molecularly

CME Outfitters, LLC Podcasts
Actionable Opportunities for Molecularly Classified Endometrial Cancers

CME Outfitters, LLC Podcasts

Play Episode Listen Later Mar 12, 2024 34:35


PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 6, 2023 47:24


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 6, 2023 47:21


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 6, 2023 47:24


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Internal Medicine CME/CNE/CPE Video Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 6, 2023 47:24


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 6, 2023 47:21


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 6, 2023 47:21


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 6, 2023 47:21


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Clinical Pharmacology CME/CNE/CPE Video
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Dec 6, 2023 47:24


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 6, 2023 47:21


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PeerView Gastroenterology CME/CNE/CPE Video Podcast
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 6, 2023 47:24


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.Co-Chair/PlannerShubham Pant, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

care phd cancer md consultants pfizer advisor outcomes elevating astrazeneca targeted institution btc md phd medical education sanofi josep pant evolving role bristol myers squibb her2 shubham planning committee accreditation council janssen pharmaceuticals daiichi sankyo seagen jazz pharmaceuticals servier tabernero pvi molecularly continuing medical education accme pharmacy education acpe menarini merck sharp dohme mirati therapeutics practice aids merck serono hoffmann la roche ltd peerview institute reviewer disclosuresplanners grant research support disclosure policyall astellas pharma inc inspirna cardiff oncology arcus biosciences scorpion therapeutics boehringer ingelheim international gmbh stock shareholder ipsen pharma ngm biopharmaceuticals zymeworks inc
PaperPlayer biorxiv neuroscience
A molecularly-defined non-redundant subpopulation of OPCs controls the generation of myelinating oligodendrocytes during postnatal development.

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Jul 29, 2023


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.28.550937v1?rss=1 Authors: Moghimyfiroozabad, S., Paul, M. A., Bellenger, L., Selimi, F. Abstract: Oligodendrocyte precursor cells (OPCs) are a class of glial cells that uniformly tiles the whole central nervous system. They play several key functions across the brain including the generation of oligodendrocytes and the control of myelination. Whether the functional diversity of OPCs is the result of genetically defined subpopulations or of their regulation by external factors has not been definitely established. We discovered that a subpopulation of OPCs found across the brain is defined by the expression of C1ql1, a gene previously described for its synaptic function in neurons. This subpopulation starts to appear during the first postnatal week in the mouse brain. Ablation of C1ql1-expressing OPCs in the mouse is not compensated by the remaining OPCs, and results in a massive lack of oligodendrocytes and myelination in many brain regions. Therefore, C1ql1 is a molecular marker of a functionally non-redundant subpopulation of OPCs, which controls the generation of myelinating oligodendrocytes. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 54:00


Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 54:00


Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 53:59


Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

PeerView Clinical Pharmacology CME/CNE/CPE Video
Ilya M. Nasrallah, MD, PhD - Navigating the New Era of Molecularly Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 28, 2023 53:59


Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

Targeted Talks
S4 Ep8: Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer

Targeted Talks

Play Episode Listen Later Jun 23, 2023 21:12


The Howie Carr Radio Network
Morning Minute: Lab Leak is "Molecularly Impossible" - 3.23.23

The Howie Carr Radio Network

Play Episode Listen Later Mar 23, 2023 2:21


Who are we supposed to believe? Our own logic or the guy who is now telling us a raccoon-dog might be COVID's original mammal?

PaperPlayer biorxiv neuroscience
A molecularly defined and spatially resolved cell atlas of the whole mouse brain

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Mar 7, 2023


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.06.531348v1?rss=1 Authors: Zhang, M., Pan, X., Jung, W., Halpern, A., Eichhorn, S. W., Lei, Z., Cohen, L., Smith, K. A., Tasic, B., Yao, Z., Zeng, H., Zhuang, X. Abstract: In mammalian brains, tens of millions to billions of cells form complex interaction networks to enable a wide range of functions. The enormous diversity and intricate organization of cells in the brain have so far hindered our understanding of the molecular and cellular basis of its functions. Recent advances in spatially resolved single-cell transcriptomics have allowed systematic mapping of the spatial organization of molecularly defined cell types in complex tissues. However, these approaches have only been applied to a few brain regions and a comprehensive cell atlas of the whole brain is still missing. Here, we imaged a panel of greater than 1,100 genes in ~8 million cells across the entire adult mouse brain using multiplexed error-robust fluorescence in situ hybridization (MERFISH) and performed spatially resolved, single-cell expression profiling at the whole-transcriptome scale by integrating MERFISH and single-cell RNA-sequencing (scRNA-seq) data. Using this approach, we generated a comprehensive cell atlas of greater than 5,000 transcriptionally distinct cell clusters, belonging to ~300 major cell types, in the whole mouse brain with high molecular and spatial resolution. Registration of the MERFISH images to the common coordinate framework (CCF) of the mouse brain further allowed systematic quantifications of the cell composition and organization in individual brain regions defined in the CCF. We further identified spatial modules characterized by distinct cell-type compositions and spatial gradients featuring gradual changes in the gene-expression profiles of cells. Finally, this high-resolution spatial map of cells, with a transcriptome-wide expression profile associated with each cell, allowed us to infer cell-type-specific interactions between several hundred pairs of molecularly defined cell types and predict potential molecular (ligand-receptor) basis and functional implications of these cell-cell interactions. These results provide rich insights into the molecular and cellular architecture of the brain and a valuable resource for future functional investigations of neural circuits and their dysfunction in diseases. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

PaperPlayer biorxiv neuroscience
A molecularly distinct accumbal-to-lateral hypothalamic circuit modulates food seeking and consumption

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Feb 28, 2023


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.27.530275v1?rss=1 Authors: Liu, Y., Zhao, Z., Xie, G., Chen, R., Zhang, Y. Abstract: Understanding the mechanism of energy homeostasis is expected to lead to effective treatment to obesity and metabolic diseases1,2. However, energy homeostasis is a complicated process largely controlled by neuronal circuits in the hypothalamus and brainstem3-5, whereas reward and motivation of food intake are mainly controlled by the limbic regions6 and cerebral cortex7,8. Although the limbic and hypothalamus connection like Nucleus Accumbens shell (NAcSh) to the lateral hypothalamus (LH) circuit has been reported to regulate feeding9,10, the neuron subtypes involved, and how do the humoral/neuronal signals coordinate to direct feeding behavior remain unknown. Here we show that the projection from dopamine receptor D1(Drd1)- and Serpinb2-expressing subtype to leptin receptor (LepR) expressing neurons in LH modulates food seeking and consumption. We demonstrate that the Serpinb2+ neuronal activity is dynamically modulated during feeding. Conversely, chemo/optogenetics-mediated modulation of Serpinb2+ neurons bidirectionally regulate food seeking and consumption. Importantly, circuitry stimulation revealed the NAcShSerpinb2[->]LHLepR projection controls refeeding and overcomes leptin-mediated feeding suppression. Ablation of NAcShSerpinb2 neurons could decrease body weight. Together, our study reveals a molecularly distinct accumbal-to-lateral hypothalamic neural circuit that controls internal state-dependent food consumption, which provides a promising therapeutic target for anorexia and obesity. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

PaperPlayer biorxiv cell biology
Excitable dynamics in a molecularly-explicit model of cell motility: Mixed-mode oscillations and beyond

PaperPlayer biorxiv cell biology

Play Episode Listen Later Oct 30, 2022


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.10.28.514275v1?rss=1 Authors: Plazen, L., Khadra, A. Abstract: Mesenchymal cell motility is mainly regulated by two members of the Rho-family of GTPases, called Rac and Rho. The mutual inhibition exerted by these two proteins on each other's activation and the promotion of Rac activation by an adaptor protein called paxillin have been implicated in driving cellular polarization comprised of front (high active Rac) and back (high active Rho) during cell migration. Mathematical modeling of this regulatory network has previously shown that bistability is responsible for generating a spatiotemporal pattern underscoring cellular polarity called wave-pinning when diffusion is included. We previously developed a 6D reaction-diffusion model of this network to decipher the role of Rac, Rho and paxillin (along with other auxiliary proteins) in generating wave-pinning. In this study, we simplify this model through a series of steps into an excitable 3D ODE model comprised of one fast variable (the scaled concentration of active Rac), one slow variable (the maximum paxillin phosphorylation rate - turned into a variable) and a very slow variable (a recovery rate - also turned into a variable). We then explore, through slow-fast analysis, how excitability is manifested by showing that the model can exhibit relaxation oscillations (ROs) as well as mixed-mode oscillations (MMOs) whose underlying dynamics are consistent with a delayed Hopf bifurcation. By reintroducing diffusion and the scaled concentration of inactive Rac into the model, we obtain a 4D PDE model that generates several unique spatiotemporal patterns that are relevant to cell motility. These patterns are then characterized and their impact on cell motility are explored by employing the cellular potts model (CPM). Our results reveal that wave pinning produces purely very directed motion in CPM, while MMOs allow for meandering and non-motile behaviours to occur. This highlights the role of MMOs as a potential mechanism for mesenchymal cell motility. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

The Plant-Based Morning Show
National Coffee Day, NBA Stars Buy Pickleball Team, Project Pollo, Nestle's Animal-Free Dairy is Molecularly Equivalent to Whey Protein (Is this a Good Thing?)

The Plant-Based Morning Show

Play Episode Listen Later Sep 29, 2022 40:22


Thursday, September 29th — It's National Coffee Day! In today's show we talk about: NBA Players Buy Pickleball Team (CNN) Project Pollo (Plant-Based News) Nestle Partners with Perfect Day to Make Animal-Free Dairy (Plant-Based News) Microbial Fermentation to Replicate French Cheese (VegNews) The Plant-Based Morning Show is presented by Complement. Tune in live on Instagram (@nomeatathlete_official and @complement) every weekday at 11am Eastern! Follow @realmattfrazier and @rockcreekrunnerfor more.

PaperPlayer biorxiv neuroscience
Experience-dependent flexibility in a molecularly diverse central-to-peripheral auditory feedback system

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Sep 27, 2022


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.26.509230v1?rss=1 Authors: Frank, M., Sitko, A., Suthakar, K., Torres Cadenas, L., Hunt, M., Yuk, M. C., Weisz, C., Goodrich, L. Abstract: Brainstem olivocochlear neurons (OCNs) modulate the earliest stages of auditory processing through feedback projections to the cochlea and have been shown to influence hearing and protect the ear from sound-induced damage through unclear mechanisms. Here, we used single-nucleus sequencing, anatomical reconstructions, and electrophysiology to characterize OCNs during postnatal development and after sound exposure. We identified markers for known OCN subtypes, medial (MOC) and lateral (LOC) OCNs, and show that they express distinct cohorts of physiologically relevant genes that change over development. In addition, we discovered a neuropeptide-enriched LOC subtype that produces Neuropeptide Y along with other neurotransmitters. Throughout the cochlea, both LOC subtypes extend arborizations over wide frequency domains. Moreover, LOC neuropeptide expression is strongly upregulated days after acoustic trauma, potentially providing a sustained protective signal to the cochlea. OCNs are therefore poised to have diffuse, dynamic effects on early auditory processing over timescales ranging from milliseconds to days. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

PaperPlayer biorxiv neuroscience
Single-Cell Transcriptomic Profiling of the Zebrafish Inner Ear Reveals Molecularly Distinct Hair Cell and Supporting Cell Subtypes

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Sep 10, 2022


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.08.507120v1?rss=1 Authors: Shi, T., Beaulieu, M. O., Saunders, L. M., Fabian, P., Trapnell, C., Segil, N., Crump, J. G., Raible, D. W. Abstract: A major cause of human deafness and vestibular dysfunction is permanent loss of the mechanosensory hair cells of the inner ear. In non-mammalian vertebrates such as zebrafish, regeneration of missing hair cells can occur throughout life. While a comparative approach has the potential to reveal the basis of such differential regenerative ability, the degree to which the inner ears of fish and mammals share common hair cells and supporting cell types remains unresolved. Here we perform single-cell RNA sequencing of the zebrafish inner ear at embryonic through adult stages to catalog the diversity of hair cell and non-sensory supporting cells. We identify a putative progenitor population for hair cells and supporting cells, as well as distinct hair cells and supporting cell types in the maculae versus cristae. The hair cell and supporting cell types differ from those described for the lateral line system, a distributed mechanosensory organ in zebrafish in which most studies of hair cell regeneration have been conducted. In the maculae, we identify two subtypes of hair cells that share gene expression with mammalian striolar or extrastriolar hair cells. In situ hybridization reveals that these hair cell subtypes occupy distinct spatial domains within the two major macular organs, the utricle and saccule, consistent with the reported distinct electrophysiological properties of hair cells within these domains. These findings suggest that primitive specialization of spatially distinct striolar and extrastriolar hair cells likely arose in the last common ancestor of fish and mammals. The similarities of inner ear cell type composition between fish and mammals also support using zebrafish as a relevant model for understanding inner ear-specific hair cell function and regeneration. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 6, 2022 36:17


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 6, 2022 36:22


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Sep 6, 2022 36:22


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 6, 2022 36:17


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Sep 6, 2022 36:17


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Sep 6, 2022 36:22


Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

PeerView Gastroenterology CME/CNE/CPE Video Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 16, 2021 70:58


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 16, 2021 70:47


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 16, 2021 70:58


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 16, 2021 70:47


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 16, 2021 70:47


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 16, 2021 70:58


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 16, 2021 70:47


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 16, 2021 70:58


Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

The Wendy Love Edge Show
Season 5, Episode 15: Let's Talk About The Entourage Effect and Cannabinoids

The Wendy Love Edge Show

Play Episode Listen Later Sep 7, 2021 59:30


The Wendy Love Edge Show does not dispense medical advice and all your health choices are your own. Guest Host: Candis Dyer, Host of Cannacorner and Ask Mary, and founder of The Human Solution International Texas Chapter. Guests: Joshua Graston- Joshua Graston is the Lead Formulator for Bee Elevated, a licensed processor in the Oklahoma Medical Marijuana Market. He is one of the leading Ethanol Extraction artists in the Nation and a Modern Day Alchemist. He is also the Head Science Writer for Cannabis Oklahoma Magazine. He is renowned for discovering Time Release Cannabis using a Multi-Lipid Delivery System. This technology allows for multiple waves of effects from a single ingested capsule or edible. In addition, he discovered the method to Molecularly bind Terpenes to Cannabinoids to elicit a strain specific entourage effect in an orally consumable form. Joshua is a product of the Future4200 and Grasscity forums, having spent years as a patient studying the works of the free market pioneers like: Greywolf, Ichiban, EloquentSolotions, PsychadelicSam and BadkittySmiles. Cindy Moffitt- Cindy Moffitt is one of the founders of Natural State Cannamoms and a cannabis educator and patient. Dandelion Heart- Our musical guest this week is Dandelion Heart https://dandelionheartband.com/home Cannabis Expert MD, Dr. Brian Nichol - https://cannabisexpertmd.com Miss Teddi- @learnfromteddi The Wendy Love Edge Show is written and created by Wendy Love Edge Producer: A Edge Productions Editing: Flint Woods Sponsors: Karas Healthcare The Relevnt App Purely Natural CBD Fayetteville and Bentonville Lit Premium Smoking Supplies Highlands Residential Mortgage 131 Inclusion Gallery aliceCBD --- Support this podcast: https://anchor.fm/thewendyloveedgeshow/support

Keeping Current
Realizing the Opportunity of Molecularly Guided Therapy: How Do We Accelerate the Revolution?

Keeping Current

Play Episode Listen Later Aug 26, 2021 50:48


An expert multidisciplinary panel provide unique perspectives on the broader application of genomic profiling and implications for clinical practice and healthcare systems. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/956958?src=mkm_podcast_addon_956958

Keeping Current
New Molecularly Guided Therapies in Advanced/Metastatic Cholangiocarcinoma: What You Need to Know

Keeping Current

Play Episode Listen Later Jun 21, 2021 35:24


Expert faculty discuss molecular-guided therapies for the treatment of cholangiocarcinoma. Credit available for this activity expires: 6/18/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/953096?src=mkm_podcast_addon_953096

Keeping Current
Molecularly Guided Therapy in Oncology Practice: The Evolving State of the Art

Keeping Current

Play Episode Listen Later May 25, 2021 35:39


Drs Cook and Normanno present and discuss the latest developments in comprehensive genomic profiling and implications for practice. Credit available for this activity expires: 5/24/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/950841?src=mkm_podcast_addon_950841

The Anti-Doping Podcast
52 - Developing Molecularly Imprinted Polymers for Anti-Doping - Rachel Hand, PhD

The Anti-Doping Podcast

Play Episode Listen Later Apr 20, 2021 25:28


Dr. Rachel Hand is a Research Fellow in Polymer Chemistry at The University of Warwick. In this episode, Dr. Hand discusses her work in the area of advancements in molecularly imprinted polymers and their role in anti-doping as well as her experiences working with the PCC on a recent research project. Plus, we talk about social media and its role in facilitating scientific collaboration in clean sport.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2021 99:25


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Gastroenterology CME/CNE/CPE Video Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 1, 2021 99:51


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2021 99:25


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2021 99:25


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 1, 2021 99:51


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 1, 2021 99:51


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2021 99:25


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 1, 2021 99:51


Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

IJGC Podcast
Role of Trastuzumab in Uterine Papillary Serous Tumors with Amanda Fader

IJGC Podcast

Play Episode Listen Later Jan 14, 2021 28:02


In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Amanda Fader to discuss the role of trastuzumab in uterine papillary serous tumors. Dr. Fader is an Associate Professor of Gynecology and Obstetrics, Vice Chair of Gynecologic Surgical Operations and Director of the Center for Rare Gynecologic Cancers at Johns Hopkins School of Medicine. She is recognized internationally as a rare uterine and ovarian cancer expert and is an active member of NRG Oncology and helps develop and co-lead innovative gynecologic cancer clinical trials. Highlights: • Uterine serous carcinoma (USC) is a biologically aggressive endometrial cancer subtype that accounts for a disproportionately high rate of endometrial cancer-related deaths. • 25-30% of women with both early and advanced stage USC will have HER2 positive tumors. • Molecularly-based therapeutic approaches in USC are increasing. • Trastuzumab, an anti-HER2 therapy, in combination with platinum/taxane-based chemotherapy improves survival outcomes for women with HER2 positive USC. • A randomized, Phase III cooperative group study is planned to study additional anti-HER2 therapies in women with all stages of USC.

Bilim 101
Gündem 101 - 2020/35

Bilim 101

Play Episode Listen Later Aug 28, 2020 10:51


Bulunduğumuz haftanın bilim dünyasından önemli gelişmeleri sizler için derledik. Molecularly engineered photocatalyst sheet for scalable solar formate production from carbon dioxide and water. https://doi.org/10.1038/s41560-020-0678-6 Pre extinction demographic stability and genomic signatures of adaptation in the woolly rhinoceros. https://doi.org/10.1016/j.cub.2020.07.046 Tiny elephant shrew resurfaces after more than 50 years on lost species list. https://www.npr.org/2020/08/24/905350284/researcher-identifies-tiny-mammal-last-documented-in-1968 SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. https://doi.org/10.1101/2020.07.14.20151126 Bize 101.podcast.info@gmail.com adresinden ulaşabilirsiniz.

PaperPlayer biorxiv neuroscience
Pain and itch processing by subpopulations of molecularly diverse spinal and trigeminal projection neurons

PaperPlayer biorxiv neuroscience

Play Episode Listen Later Jun 19, 2020


Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.06.17.156091v1?rss=1 Authors: Wercberger, R., Braz, J. M., Weinrich, J. A., Basbaum, A. I. Abstract: A remarkable molecular and functional heterogeneity of the primary sensory neurons and dorsal horn interneurons transmits pain- and or itch-relevant information, but the molecular signature of the projection neurons that convey the messages to the brain is unclear. Here, using retro-TRAP (translating ribosome affinity purification) and RNA-seq we reveal extensive molecular diversity of spino- and trigeminoparabrachial projection neurons, which to date are almost exclusively defined by their expression of the neurokinin 1 receptor (NK1R). Among the many genes identified, we highlight distinct subsets of Cck+, Nptx2+, Nmb+, and Crh+ expressing projection neurons. By combining in situ hybridization of retrogradely labeled neurons with Fos-based assays we also demonstrate significant functional heterogeneity, including both convergence and segregation of pain- and itch-provoking inputs onto molecularly diverse subsets of NK1R- and non-NK1R-expressing projection neurons. The current study provides the first comprehensive investigation into the molecular profiles and functional properties of projection neuron subtypes. Copy rights belong to original authors. Visit the link for more info

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 8, 2020 62:02


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.

Hot Plate
One is the Loneliest Flavour (Molecularly Speaking)

Hot Plate

Play Episode Listen Later May 26, 2020 31:52


Are you drinking too much? Will computers shape the future of flavour? The urban gardening revolution. And do you want VR with your dinner?

West Wind (Video)
Dr. Alex Drilon: Clinical Research and the Changing Practice of Managing Molecularly-Defined, Narrow Subgroups

West Wind (Video)

Play Episode Listen Later Mar 26, 2019 12:18


Drs. Jack West & Alex Drilon, from Memorial Sloan-Kettering, discuss opportunities & challenges of studying narrow molecularly-defined patient subgroups, (MET, RET, TRK, & others), along with the increasingly active role of online patient groups.

West Wind (Audio)
Dr. Alex Drilon: Clinical Research and the Changing Practice of Managing Molecularly-Defined, Narrow Subgroups

West Wind (Audio)

Play Episode Listen Later Mar 26, 2019 12:18


Drs. Jack West & Alex Drilon, from Memorial Sloan-Kettering, discuss opportunities & challenges of studying narrow molecularly-defined patient subgroups, (MET, RET, TRK, & others), along with the increasingly active role of online patient groups.

Gluten Free RN
Why No Dairy on a Gluten-Free Diet? EP068

Gluten Free RN

Play Episode Listen Later Apr 20, 2018 21:55


If you’re just getting used to eliminating gluten from your diet, it may feel like a burden to remove dairy as well—especially if you’re a fan of comfort foods like cheese and ice cream. Why exactly do many practitioners recommend a gluten- AND dairy-free diet to patients diagnosed with celiac disease and non-celiac gluten sensitivity? The Gluten Free RN is walking us through the similarities between gliadin and casein, explaining how the proteins found in gluten, milk and cheese impact our brains. She discusses how Marsh 1 damage from celiac disease leads to an inability to break down the sugar in milk and why we crave the very foods that are making us sick. Nadine shares the story of a young man with autism whose health improved once his family went gluten-free, describing the well-documented gut-brain connection and how the right high-fat diet can repair the neurological system. Listen in for the Gluten Free RN’s insight around dairy replacement options and get empowered to reclaim your health with a gluten- and diary-free diet! What’s Discussed:  The similarities between the gluten and casein proteins Molecularly very similar, bodies read as toxins Both capable of crossing blood-brain barrier How the casein protein impacts the brain Causes inflammation, hypoxia (decrease flow of oxygen) Brain fog, anxiety, depression, irritability and fatigue The effect of Marsh 1 damage due to celiac disease Microvilli damaged or destroyed Can’t produce enzymes that break down sugar in milk How gluten and casein proteins act as exorphins Bind with opium receptors in brain Crave foods that make us sick Nadine’s recommendations for dairy replacements Coconut, hemp, almond or hazelnut milk Kite Hill and NuCulture cheese options How a gluten-free diet helped a young man with autism More interaction with family, fewer GI issues High-fat diet repairs neurological system The story of Dr. Terry Wahls Diagnosed with MS, healed on gluten-free diet Resources: Aroy’d Coconut Milk Kite Hill NuCulture Foods Mary’s Gone Crackers Jilz Crackers Dr. Terry Wahls’ TED Talk The Wahls Protocol  by Dr. Terry Wahls Dr. Terry Wahls’ Website Connect with Nadine: Instagram Facebook Contact via Email ‘Your Skin on Gluten’ on YouTube Melodies of the Danube Gluten-Free Cruise with Nadine Books by Nadine: Dough Nation: A Nurse's Memoir of Celiac Disease from Missed Diagnosis to Food and Heal

GRACEcast Lung Cancer Video
Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 14, 2016 4:44


Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.

GRACEcast ALL Subjects audio and video
Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 14, 2016 4:44


Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.

GRACEcast
Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?

GRACEcast

Play Episode Listen Later Mar 14, 2016 4:44


Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.

GRACEcast
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care

GRACEcast

Play Episode Listen Later Nov 2, 2014 12:20


Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.

GRACEcast Lung Cancer Video
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 2, 2014 12:20


Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.

GRACEcast ALL Subjects audio and video
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 2, 2014 12:20


Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.

GRACEcast Lung Cancer Video
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 30, 2014 24:31


Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.

GRACEcast ALL Subjects audio and video
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 30, 2014 24:31


Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.

GRACEcast
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups

GRACEcast

Play Episode Listen Later Oct 30, 2014 24:31


Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.

TechStuff
Molecularly Gastronomical

TechStuff

Play Episode Listen Later Jul 24, 2013 56:30


What is food science? What is molecular gastronomy? How do sous vide machines work? Learn more about your ad-choices at https://news.iheart.com/podcast-advertisers

Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 15/19
Molecularly targeted therapy on a new preclinical mouse model for gastric neuroendocrine tumors

Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 15/19

Play Episode Listen Later Jul 18, 2013


Neuroendocrine tumors are a heterogeneous group of malignancies with an increasing prevalence. Since there is not much progress in therapy, model systems are urgently needed. We have a CEA424-SV40 TAg transgenic mouse model which develops spontaneous tumors in the antral region of the stomach. In addition, several cell lines derived from the tumor were established. Gene expression analysis of the tumor tissue as well as cell lines revealed neuroendocrine markers. Therefore we further characterized this model with special emphasis on the cells of origin and used it for testing new targeted treatment protocols. To analyze CEA424-SV40 TAg mouse model in more detail, tumor tissue as well as the cell lines derived from the primary tumor were investigated by immunohistochemistry, immunofluorescence, western blot, and ELISA. Antibodies used were directed at SV40 TAg, Ki-67, chromogranin A, chromogranin B, secretin, H+-K+-ATPase, glucagon, and transcription factors NeuroD1 and Nkx2.2. Plasma hormone levels of serotonin and secretin were measured by ELISA. Immunostainings of SV40 TAg and Ki-67 revealed highly proliferative tumors cells. The tumors stained intensively for the neuroendocrine markers chromogranin A, chromogranin B, secretin and glucagon. The tumor tissue as well as the cell lines expressed transcription factors NeuroD and Nkx2.2, which are involved in the differentiation of the neuroendocrine lineage. Hormone levels of serotonin and secretin in the plasma of the transgenic mice were dramatically elevated when compared with normal littermates, thus supporting the neuroendocrine phenotype. As the neuroendocrine phenotype of CEA424-SV40 TAg transgenic mouse was confirmed, molecularly targeted therapies were tested in this model system both in vitro and in vivo. Cell lines were tested for drug sensitivity with mTOR inhibitors (RAD001, NVP-BEZ235), paclitaxel, E2F inhibitor, HSP90 inhibitor, and p53 stabilizer Nutlin-3a. All the drugs tested in vitro could efficiently inhibit cell proliferation in a dose dependent manner. From these drugs the mTOR inhibitor RAD001 was chosen for the in vivo experiment. Daily feeding of 10 mg/kg RAD001 inhibited the tumor development and prolonged the survival time of the CEA424-SV40 TAg transgenic mice dramatically. The effects of the RAD001 treatment on tumor cells were achieved mainly through inactivating mTOR-p70S6K and mTOR-4EBP1 signaling as proven by western blot and immunohistochemistry. Still, some cells must develop escape mechanisms, since the tumor tend to grow. To gain a better understanding of the T antigen transforming mechanisms as well as the possible escape mechanisms, some efforts were made on the tumor originating cells in the CEA424-SV40 Tag transgenic mouse model. Possible candidates for these tumor originating cells in the stomach are the newly described epithelial as well as mesenchymal stem cells. In a first attempt, the expression feature of epithelial and mesenchymal stem cell markers were analyzed. Established cell lines as well as tumor tissue from the tumor bearing mice were investigated by reverse transcription PCR (RT-PCR), immunohistochemistry, immunofluorescence, western blot, and microarray analysis. From several markers analyzed, the tumor cell lines showed a high expression level of the potential epithelial stem cell marker Bmi1 in RT-PCR and cDNA expression array. This could be further substantiated by western-blotting and immunostaining. Consequently, Bmi1 message could also be found in the growing tumors both in mRNA and protein levels. Experiments using siRNA to knock down the SV40-TAg expression showed that the Bmi1 expression went down in the cell lines thus showing the interrelationship. On the other hand, the mesenchymal stem cell marker Etv1 was also found to be expressed in the tumor tissue and cell lines derived from the tumor. More interestingly, Etv1 expression level was up-regulated over the time course of the tumor development. From these, an Etv1 positive mesenchymal cell could be a possible candidate for transformation. Since the CEA-promoter used for the generation of the T-antigen transgenic animals contains Etv1 binding sites, it is tempting to speculate, that this may drive the transcription of the T antigen. In conclusion, our data provide convincing evidence that CEA424-SV40 TAg mice are a clinically relevant model for neuroendocrine tumor. Testing of molecularly targeted therapies both in vitro and in vivo offered promising candidates for further clinical evaluation. Thus, this new model system could be of great value not only for studies on the mechanisms of how SV40 TAg induces neuroendocrine tumors but also for exploring novel targeted therapy in a preclinical setting.

GRACEcast Lung Cancer Video
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later May 17, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

GRACEcast ALL Subjects audio and video
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 17, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

GRACEcast
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)

GRACEcast

Play Episode Listen Later May 17, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

GRACEcast ALL Subjects audio and video
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 17, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

GRACEcast
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

GRACEcast

Play Episode Listen Later May 17, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

GRACEcast Lung Cancer Audio
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later May 16, 2013 11:35


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).

4th IMPAKT Breast Cancer Conference
Molecularly characterising triple negative breast cancer: Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

4th IMPAKT Breast Cancer Conference

Play Episode Listen Later May 29, 2012 5:07


Prof Jorge Reis-Filho talks to ecancer about molecularly characterising triple negative breast cancer at IMPAKT 2012 in Brussels, May 2012. At the molecular level, triple negative breast cancer is not a single disease. There are a larger number of heterogeneous tumours, which means that this disease cannot be analysed in the same way as other types of breast cancer. The differences between diseases are the biological starting point for testing different therapeutic agents against triple negative breast cancer. The different subtypes of tumours can each respond differently to strategies, but will give prognostic signatures that will point to a quick and clear prognosis. However, there are complications with what type of prognostic signatures can be used in triple negative cases.

Journal of Clinical Oncology (JCO) Podcast
Are Lung Cancers with BRAF Mutations Another Molecularly Defined Subgroup of Patients?

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Apr 11, 2011 5:08


In this week's podcast, Dr. Jaine discusses the recent manuscript by Paik and colleagues evaluating BRAF mutations in patients with advanced lung cancer. The potential impact of BRAF mutations and outcomes with current therapies for lung cancer are discussed.

Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 03/06
Molecularly targeted imaging and radionuclide therapy of non-thyroidal tumors following viral and non-viral sodium iodide symporter (NIS) gene delivery

Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 03/06

Play Episode Listen Later Oct 28, 2010


Thu, 28 Oct 2010 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/13695/ https://edoc.ub.uni-muenchen.de/13695/1/Klutz_Kathrin.pdf Klutz, Kathrin

Research Podcast | Memorial Sloan Kettering Cancer Center
How Modern Genomic Techniques Can Be Used to Identify Novel Mutations in Human Cancers and to Develop Molecularly Targeted Therapies (Part 2 of 3) 2009

Research Podcast | Memorial Sloan Kettering Cancer Center

Play Episode Listen Later Dec 30, 2009 40:38


Runtime 40:38 Physician-scientist, Ross Levine, discusses how the study of genomic techniques can lead to the development of new treatments. read more

Lung Cancer Update
LCUTT1 2007 | Novel Molecularly Targeted Agents in Lung Cancer

Lung Cancer Update

Play Episode Listen Later Nov 21, 2007 2:55


LungCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Novel Molecularly Targeted Agents in Lung Cancer. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

interview md targeted lung cancer molecularly neil love clinical investigator think tank thinktank proceedings
Clinician's Roundtable
The new molecularly targeted drugs

Clinician's Roundtable

Play Episode Listen Later Aug 6, 2007


Guest: Jeffrey Settleman, PhD Host: Bruce Bloom, DDS, JD We've been fighting cancer for almost 50 years without real success. Could molecular targeted drugs finally be the answer?